The RELAY study also reported that erlotinib plus ramucirumab resulted in a longer PFS period than erlotinib plus placebo in treatment-naïve EGFR-mutant NSCLC (19.4 vs. 12.4 months, p < 0.001) [17]. Here, EGFR is linked to non-small cell lung carcinoma.